Background: Light transmission aggregometry (LTA) is the current gold standard method for assessing platelet function. Recently, a new parameter called the ADP-induced platelet aggregation level (APAL) was developed to aid interpretation of LTA results. APAL is a score from 0.0 to 10.0 calculated based on platelet aggregation patterns upon exposure to 1 µM and 10 µM adenosine diphosphate (ADP) and is determined using an automated coagulation analyzer.

Aims: We compared obtained APAL and P2Y12 reaction unit (PRU) values and % inhibition on VerifyNow P2Y12 assay for the patients with cerebrovascular disease.

Methods: 42 patients who have received antiplatelet therapy were studied. Platelet function tests were performed on CS-2400 for APAL and VerifyNow P2Y12 assay was used for PRU and % inhibition.

Results: Moderate correlations were observed between APAL and PRU (r = 0.64, p < 0.001), APAL and % inhibition (r = -0.74, p < 0.001), and PRU and % inhibition (r = -0.83, p < 0.001). The optimal threshold for APAL was 8.2 for PRU (threshold = 240) and 8.1 for % inhibition (threshold = 26%). The percentage of agreement between the above thresholds was 90.9%, 77.3%, and 84.1% between PRU and APAL, % inhibition and APAL, and PRU and % inhibition, respectively.

Conclusions: The newly-developed APAL system exhibits moderate correlation with PRU and % inhibition. All three results showed similar agreement rates. Moreover, since APAL is the result of LTA and can be measured at a lower cost than that required for VerifyNow, it is expected that the regular monitoring of antiplatelet therapy will be possible even in facilities where it has been difficult owing to cost.

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/correlation-between-the-verifynow-p2y12-assay-and-the-newly-developed-apal-system-in-neuroendovascular-patients/